ClinicalTrials.gg
CompletedNCT01167322Updated Apr 27, 2012

Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas

A Phase 3 interventional study of NPC-07 for oral administration in Malignant Glioma, sponsored by Nobelpharma. Completed at 3 sites in Japan. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-04-27.

Sponsored by Nobelpharma · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing Aminolevulinic Acid in Glioma — 2 open to participants now, 4 under way, 1 of them phase 3. Aminolevulinic Acid · Glioma.

Enrollment
8th of 16
45 · median 39
Started
2010
with 2 others
Phase 3
3 of 16
1 open now
Registered
6th of 16
by date
Lead sponsor
1 of 16
Nobelpharma

Among the 16 studies testing Aminolevulinic Acid in Glioma, this one is the 8th largest by enrollment, is one of 3 that started in 2010, is one of 3 in phase 3, and was the 6th registered.

Glioma

1,453 studies on the registry are indexed under Glioma; 349 are open to participants now.

Browse Glioma studies →

Open to participants now

2 of the 16 studies testing Aminolevulinic Acid in Glioma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Aminolevulinic Acid

Aminolevulinic Acid: first FDA approval 1999 (LEVULAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 56 (21%) stop at 75 or younger; 62 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing Aminolevulinic Acid in Glioma, or all of them as a file.
02

Study summary

The aim of the present Phase III study is to assess the positive predictive value of NPC-07 (5-aminolevulinic acid hydrochloride) induced tissue fluorescence, safety and pharmacokinetics following a single dose of NPC-07 orally, at a dose of 20mg/kg/body weight, 3 hours prior to induction of anaesthesia for surgery of patients with newly or recurrent malignant glioma (WHO grades III/IV).

Positive predictive value will be confirmed by percentage of patients showing positive tumor cell identification in all biopsies taken from areas of strong and weak fluorescence. This study will be divided into two stages. After reviewing of the result of safety and pharmacokinetics of NPC-07 in small number of subjects by independent safety monitoring committee, more subjects will receive NPC-07 in Step II.

03

Conditions studied

  • Malignant Glioma

Browse trials for

Keywords

  • NPC-07, 5-ALA, photodynamic diagnosis, pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 70 years.
  • Radiological suspicion of newly- or recurrent malignant glioma (WHO grades III/IV).
  • Indication for surgical tumor resection.
  • Performance Score of 60 or higher.
  • Provides signed prior to any study procedures.
  • Comply with visit schedule and other rules for patients in study protocol.

Exclusion criteria

Exclusion Criteria:

  • Porphyria, to porphyrins.
  • Renal insufficiency: Creatinine 2.0 mg/dL or higher
  • Hepatic insufficiency: 100 IU/L or higher, AST 100 IU/L or higher, γ-GTP 100 IU/L or higher or total 3 mg/dL or higher
  • Chemotherapy or other treatment for other malignant tumors
  • Females who are pregnant or potentially childbearing or are breastfeeding
  • Participation in other clinical trial in the previous 1 month
  • Ineligible patient based on the judgement of the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    NPC-07

    Single administration of NPC-07 at a dose of 20mg/kg body weight

    Drug: NPC-07 for oral administration

Interventions

  • NPC-07, containing 1.5g of 5-aminolevulinic acid hydrochloride per vial, is dissolved in 50 mL of water and will be administered orally 3 hours (range 2-4 hours) prior to induction of anesthesia at a dose of 20mg/kg body weight.

    Also known as: 5-ALA, 5-aminolevulic acid hydrochloride

06

What researchers measure

Primary outcomes

  1. Positive predictive value of tissue fluorescence

    Positive predictive value of tissue fluorescence defined as the percentage of patients showing positive tumor cell identification in all 6 biopsies taken from areas of strong and weak fluorescence.

    Time frame: 1 day

Secondary outcomes

  1. Quality of fluorescent tissue

    Quality of fluorescent tissue by the judgement of the investigator

    Time frame: 1 day

  2. Positive predictive value of tissue fluorescence in each biopsy tissue sample

    Positive predictive value of tissue fluorescence at the biopsy level defined as the number of tumor positive biopsies among all biopsies taken from areas of strong and weak fluorescence.

    Time frame: 1 day

  3. Percentage of patients without residual tumor

    Percentage of patients without residual tumor in the MRI within 72 hours after surgery

    Time frame: 3 days

  4. Positive predictive value of non-fluorescent tissue at the biopsy level

    Positive predictive value of tissue fluorescence at the biopsy level defined as the number of tumor positive biopsies among the non-fluorescent tissue adjacent to fluorescent tissue areas and the tumor distant cortex with respect to tumor (if available).

    Time frame: 1 day

  5. Sensitivity as percentage of actual positives and specificity as percentage of actual negatives of fluorescence detection at the biopsy level (if available).

    Sensitivity as percentage of actual positives(True positive fraction/True positive fraction + False negative fraction)and specificity as percentage of actual negatives of fluorescence detection (True negative fraction/False positive fraction + True negative fraction) at the biopsy level (if available).

    Time frame: 1 day

  6. Safety

    AEs during study period (Day 0 to Day 28), laboratory parameter, vital signs, EKG, pO2

    Time frame: 28 days

  7. Pharmacokinetic parameters of NPC-07 and active metabolite (Cmax, AUCt, tmax, t1/2)

    Pharmacokinetic parameters of 5-ALA and PPVX (Cmax, AUCt, tmax, t1/2)

    Time frame: 2 days

07

Study locations

3 sites
  • International Medical Center, Saitama Medical University
    Hidaka, Saitama 350-1298, Japan
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
  • Kyorin University Hospital
    Mitaka, Tokyo 181-8611, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2010
First posted
Jul 22, 2010
Start
Aug 2010
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Last update
Apr 27, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01167322
Lead sponsor
Nobelpharma
Responsible party
Sponsor
First posted
Jul 22, 2010
Start date
Aug 2010
Primary completion
Dec 2011
Completion
Dec 2011
Last update
Apr 27, 2012

Study contacts

Soichiro Shibui, MD, PhD
study director · Neurosurgery & Neuro-Oncology Division, National Cancer Center Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aminolevulinic Acid

Start the discussion